 The abstract of the article discusses the structure of platelet-integrin alpha-i-beta-3 in two different states, one being the inactive bent shape and the other being the active shape when bound to a ligand. It also explains how anti-alpha-i-beta-3 drugs such as ectaphibotide can interfere with the normal hemostatic functions of alpha-i-beta-3. Finally, it provides insight into the structural differences between the two shapes and how these differences could be used to develop safer inhibitors. This article was authored by Brian D. Adair, Jen Pingshun, Mark Jaeger, and others.